Advertisement
Advertisement
U.S. markets close in 5 hours 13 minutes
Advertisement
Advertisement
Advertisement
Advertisement

Reflect Scientific, Inc. (RSCF)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
0.1110+0.0026 (+2.40%)
As of 09:33AM EDT. Market open.
Advertisement

Yahoo Finance will soon be upgrading our Conversations message board platform to provide a better experience for our users. Only comments published since April 21, 2021 will be visible on Yahoo Finance after the upgrade. If you wish to download and save any of your older comments, please submit a request via the Privacy Dashboard by no later than Aug. 15, 2022.

Sign in to post a message.
  • B
    Bryan
    Finally they get proper PR
  • R
    Richard
    More good news today......I hope the company can get in good with the "fruits" and "nuts" that run California !
  • R
    Richard
    Good update today. I hope the company announces some large scale orders and partnerships going forward.
  • S
    Stephen
    Well lads, looks like we will be holding this for a long long time.
  • A
    ANTHONY
    This company reminds me of BLFS which I had bought on the otc and made some $. I got into this one with 10 k at .12 and will add at least another 15 k for the long hall ,I see great things here also tpzc.
  • G
    G and L
    look up article " How MRNA tech blew open the door of UPS's cold chain logistics business " . Just out today 7/2 2022 . This company and it's share price will do well this year .
  • J
    JJK
    Did this get delisted?..
  • A
    Aaron
    This stock is super under valued today. Plus, the new patents for the Cryometrix. Why would this stock not go higher from her?
  • B
    BJ57
    Here is the PR!!!

    Ultra-low temperature mechanical freezers face unique issues. Lack of temperature uniformity throughout the storage volume can be a problem for both upright and chest freezers. Opening and closing the door creates a large influx of warm air causing an extended temperature recovery time. Reflect Scientific has already addressed this concern for upright freezers with its unique liquid nitrogen based Cryometrix system. A recently issued Reflect Scientific patent now addresses these concerns with a superior chest freezer design. The Cryometrix chest freezer temperature stability and resistance to warm air infiltration during opening provides a very consistent, controlled low temperature environment that can be relied upon for safely storing high value products such as CAR-T therapeutics. This patented technology provides the next level of temperature uniformity and control.
    The cold chain management of COVID vaccines continues to present challenges in storage and distribution; and we believe our patented freezer technology could have a favorable and positive impact on the current pandemic and would be a valuable asset for the distribution and storage of the current COVID-19 vaccines that require storage at extremely cold temperatures.
    On our sales front, we have several freezer systems scheduled for shipment this year, with a number of other orders anticipated in the first quarter of 2021 from multiple worldwide pharmaceutical companies; we are pleased with the level of activity we are seeing, and remain optimistic that the Company may realize positive earnings per share for 2020. The Company is presently debt free.
    In the area of cold chain management, we are continuing discussions with a major supplier of air transport containers regarding the integration of our liquid nitrogen systems to enable cooling and temperature control of sensitive payloads.
    We are still awaiting response from Operation Warp Speed, a FEMA contractor, and other organizations, from who we have received inquiries for our Cryometrix S-90 cryogenic shipping and storage system. These systems can also serve as a cold (e.g. -80C) storage unit once at destination. We do have a large-scale manufacturing capability should these inquires firm up. In terms of the competitive advantages of our products, we believe the Cryometrix liquid nitrogen freezers offer the following principal benefits versus mechanically driven ULT's or the utilization of dry ice. They can: (i) accommodate a wide range of temperature storage conditions (i.e. anywhere from room temperature to as low as -90C); (ii) have a very rapid temperature recovery from door openings, making it safer, for example, in maintaining COVID vaccines at the desired critical temperature; and (iii) the Cryometrix liquid nitrogen system has a very high operational reliability, keeping potential waste of valuable payloads to essentially zero compared to mechanically driven freezers that can be susceptible to failure.
    We do not require dry ice, which has temperature limitations. Dry ice is limited to -78.5C (the current Pfizer vaccine has been reported to require -80C); and dry ice can also present challenges with respect to handling. On the other hand, liquid nitrogen in the Cryometrix system is in a contained environment.
    Cryometrix freezers typically show higher storage capacity per footprint compared to mechanical freezers, and they have excellent temperature uniformity throughout the payload space with essentially no build-up of ice on payload. The newly granted patent for a “chest” freezer will be a welcome and important addition to our Cryometrix freezers.
    Bullish
  • r
    rameez
    Dear Shareholder,

    Thank you for your inquiry. The following information may help answer any questions you may have about Reflect Scientific Inc.

    Purchase contracts, product use, and product configuration are considered by many of our customers as a strategic asset or trade secret. Reflect Scientific does not disclose this information to the public unless express permission is granted. However, at times, Reflect will provide general information concerning products and sales via press releases and social media.

    Reflect Scientific is moving forward with innovative low-temperature refrigeration/freezer storage and transportation solutions. We invite you to follow us on Twitter @ReflectSci or Linkedin.

    Thank you for your interest in Reflect Scientific.

    Reflect Scientific Inc.
    Investor Relations
  • V
    Victor
    I am adding shares of RSCF for the following reasons:

    1. RSCF's ultra-low temperature freezers (ULTF) functionalizing by liquid nitrogen are safe, efficient, reliable and can even be operational without electricity for a certain amount of time. There is currently no other product in the world that can do that.
    2. Conservatively speaking, more than half of modern biologics (biological medications in general, not just COVID-19 vaccine) require reliable refrigeration during transit and storage. RSCF's ULTFs are well positioned to meet this growing demand, unless another company comes up with a better designed product. I've been working with biologics for more than 15 years and know this for a fact.
    3. The company has little or no debt and is already generating good revenue (relative to its currently very small size).
    4. The company has patented products that have multiple possible usage (foods, biologics, stem cells, human frozen eggs, etc.)
    5. Later on, when COVID-19 vaccines (made by more than just one or two pharmaceutical companies) are available to the general public worldwide, refrigeration for transportation (i.e. mobile freezers) and storage (i.e. stationary freezers) will be needed en masse. RSCF should at least get a slide of the demand (this is just my speculation - no proof whatsoever yet.)
    6. RSCF stock price may not go much much lower from the current level.

    Just my 1.5 cents.

    Good luck to all!
  • B
    Bama
    Year over year gains of 243% were realized for the period ending June 30, 2020 vs June 30, 2019. Gains are attributed to an increased demand for solvent chillers used in the cannabis processing market and a surge in bio-pharmaceutical manufacturing requirements for blast freezing and custom low temperature freezing solutions. Mr. Boyce, CEO of Reflect, commented, “Our Cryometrix brand freezers have become recognized in the bio-pharmaceutical market as the go to solution for rapid, precise freezing of high value products. We are now making inroads into the international market because of this recognition.”
  • n
    nito
    Mr. Kim Boyce, CEO of Reflect Scientific Inc., remarked, “Continued strong interest in the Cryometrix ultralow temperature freezers and solvent chillers has driven our successful third quarter revenues. My expectation is that the market conditions fueling our sales will prevail well into the foreseeable future. The emergence of mRNA vaccines like COVID-19, therapeutic protein drugs and other biologicals requiring ultra-cold conditions for processing, storage or transportation will serve to create a solid revenue stream for the Cryometrix ultracold refrigeration solutions.”
    Bullish
  • J
    JIMMYC
    . As an example of our Cryometrix systems advantage some recent activity has required an application where payloads are rapidly cooled, held at flexible temperature control points and shipped in bulk with a long shipping duration. The Cryometrix system is ideally suited for this application. It offers rapid cooling much more effectively than mechanical compressor driven systems, can control temperature uniformly across a wide range of set points, is capable of holding as much as 72,000 vials in one payload and could be utilized where many weeks may be required for the storage / shipping cycle without recharging the cooling system. This would be critically important in the case of distributing COVID vaccines which is currently a logistics issue under review. Reflect was recently awarded a patent for large volume transportation of pharmaceuticals like COVID vaccines.
  • A
    Anonymous
    The need is there. Just have to get some contracts going. It's inevitable. It will just take some time. But if you look at the profiles of the Execs on the RSCF website they have the connections. I am confident they are using these connections, but contracts and orders don't happen over night. Give it time. They just got their patents issued. And for all we know it could already be happening and a PR will drop when we least expect it.

    https://finance.yahoo.com/news/m-rna-vaccines-spur-innovation-in-logistics-expert-150201414.html

    ....'Daniels believes that in addition to improving cold-chain logistics for the duration of the pandemic, new technologies are likely to take hold.

    “Cryogenics companies will be a critical part of the supply chain,” he said. “Things like liquid that can be dry-frozen and unlocked and more advanced technologies are necessary for future distribution.”

    For the next level of distribution, there are lots of possibilities to work through.

    “We have to manage risk. There’s lot of technology that looks like its out of the movies,” Daniels said.

    The ultra-cold storage units states have invested in are challenging to manufacture and ship, and there is also some degree of scarcity, he explained.

    But for frozen liquid methods, it’s possible to have smaller cold storage units. And with the unmet global demand percolating, it’s especially important to focus on rural and poor infrastructure areas, he said.

    “More advanced technologies are necessary for future distribution, especially with the efficacy numbers that Pfizer and Moderna have published,” Daniels said.

    “The idea here needs to be that these technologies allow small, regional, not-as-well-funded areas to get access to these vaccines,” he said.
  • D
    D.C. Miller
    OREM, Utah , Jan. 13, 2021 (GLOBE NEWSWIRE) -- Reflect Scientific, Inc. (Symbol: RSCF), a provider of diverse products and services for the biotechnology, pharmaceutical, and transportation industries, announces a $416K sales contract for Cryometrix B-90 blast freezers
  • B
    Big M
    Old news but very relevant. I you invest in RSCF you have to read this article!

    FRI NOV 13, 2020 / 4:15 PM EST

    U.S. states race to buy ultra cold vaccine freezers, fueling supply worries

    Lisa Baertlein and Carl O'Donnell

    A portable, ultra cold freezer is shown in this undated handout picture from Stirling Ultracold in Athens, Ohio, U.S., Stirling Ultracold/Handout via

    REUTERS

    LOS ANGELES/NEW YORK (Reuters) - U.S. states, cities, and hospitals are scrambling to buy ultra-cold freezers that can safely store Pfizer Inc's (PFE.N) COVID-19 vaccine, ignoring advice from the U.S. Centers for Disease Control and Prevention (CDC) to hold off.
    The push reveals a lack of infrastructure to support a super cold vaccine campaign, including equipment to store millions of doses of Pfizer's vaccine at temperatures of minus 70 degrees Celsius (minus 94°F), significantly below the standard for vaccines of 2-8 degrees Celsius (36-46°F).
    Some specialty freezer makers warn of months-long waits for units.

    ADVERTISEMENT

    It also marks widespread wariness of the advice from the CDC, which on Aug. 26 urged healthcare providers not to purchase ultra low temperature (ULT) freezers, saying it was working on solutions for Pfizer's "very complex storage and handling requirements."
    A CDC spokeswoman on Thursday said the agency expects the first vaccine doses will be in limited quantities and rapidly deployed, reducing the need to store them in specialized freezers.
    But the news on Monday that initial results from a pivotal trial of the vaccine developed by Pfizer and German partner BioNTech (22UAy.F) showed it to be more than 90% effective has turned attention to eventual shipping and storage logistics.
    That has thrown a spotlight on makers of the niche freezers, including Thermo Fisher Scientific Inc (TMO.N), Luxembourg's B Medical Systems, Helmer Scientific and Stirling Ultracold, who are adding labor and expanding capacity.
    "I would estimate that a third of states are purchasing ultra cold storage equipment," said Claire Hannan, executive director of the Association of Immunization Managers, a nonprofit representing state and local public health officials who handle vaccines.
    The specialized freezers required by Pfizer's vaccine can cost $5,000 to $15,000.

    Moderna Inc (MRNA.O) is close to releasing efficacy results for its similar vaccine, which requires an easier to accommodate storage temperature of minus 20 degrees Celsius (minus 4°F).
    At least half a dozen states, including California, Rhode Island and New Mexico, said in published comments to the CDC that they expect to face challenges due to limited supplies of ULT freezers. A similar number told Reuters or said in public filings that they are purchasing units in anticipation of the vaccine rollout.
    Kentucky Governor Andy Beshear on Thursday called for federal funding for cold storage and said he hopes other vaccines with less onerous storage requirements get approved.
    ON BACK ORDER
    Earlier this year, due to lack of a coordinated federal response to the pandemic, states were forced to compete against each other for everything from protective N95 masks for healthcare workers to ventilators and testing equipment.
    While demand for ULT freezers is climbing, it has not entered the early pandemic's ventilator panic phase where "we had lead times of 18 months," said Rebecca Gayden, who oversees sourcing of freezers and other capital equipment at Vizient, a purchasing group used by more than 5,000 not-for-profit health systems and affiliates.

    ADVERTISEMENT
  • J
    JIMMYC
    On our sales front, we have several freezer systems scheduled for shipment this year, with a number of other orders anticipated in the first quarter of 2021 from multiple worldwide pharmaceutical companies; we are pleased with the level of activity we are seeing, and remain optimistic that the Company may realize positive earnings per share for 2020. The Company is presently debt free.
  • M
    Michael M.
    Be so kind as to indulge a 62 year old with a 100k shares bought at av .62 who has seen many a lot in 30 years of doing this and have posted on this pre-hype.
    Bear with me please.
    Warren Buffet : The stock market is very efficient at transferring wealth from the impatient to the patient.
    On this stock valuation, rehashing pre-hype post : true value last quarter .49; growth 200% at 70% margin true growth 140%, EOY true growth price giving bonus growth multiple x 1.5 = expected EOY $2.10. Looking forward mid year $5, all things in place $10 EOY 2021. That is why i stated no selling under $10 and $M shows in my account. Been there done that.
    On stock behavior: also posted spiked followed by dip, avoid buying the rip, don’t sweat the dips. One day it will rip and not look back. Buy a low dip and eat popcorn watch a movie check back at $10.
    On hype: valuations wont matter when emotions kick in as it eventually will.
    On forward expectations: it will hit $10 sooner or later and thats as solid and safe a base as u could want. Hype can blow it to $20 and that now becomes safe harbor.
    Time frame before end of 2021. Patience plz people.
    Any spike above $20 is bubble territory and I’m selling into bubble spikes. Even at todays high people you are looking at x7 within a year. Patience is virtue. Tomoro always comes.
    Ignore pumpers,dumpers and naysayers everybody gotta make money there way.
    Run numbers, understand psychology, practice patience.

    I post this for those who trying to figure this out to think on.
    Go look at the chart, it shows stock behavior, read the company reports and do some DD it shows valuation and use my calculations to predict forward price, check thermafreeze chart it shows psychology.
    This is as good an opportunity as will come your way.
    Future reference for stick buying:
    Research true value, look for well run profitable companies growing fast trading at 40% or so discount to true value then jump all over it.
    Be open to making errors and retrace what you missed to better learn.
    If you bought high dont take a loss, this stock will grow into value and more than likely blow past value on hype.
    My humble suggestions. Now back to living modestly , chopping wood to indulge the cat and people plz strive to become independently wealthy so that who is president or not, stimulus or not, transitions or not does not matter to the care of your family.
    Peace and prosperity to all
  • n
    nito
    FACT! "On our sales front, we have several freezer systems scheduled for shipment this year, with a number of other orders anticipated in the first quarter of 2021 from multiple worldwide pharmaceutical companies; we are pleased with the level of activity we are seeing, and remain optimistic that the Company may realize positive earnings per share for 2020. The Company is presently debt free.

    In the area of cold chain management, we are continuing discussions with a major supplier of air transport containers regarding the integration of our liquid nitrogen systems to enable cooling and temperature control of sensitive payloads.

    We are still awaiting response from Operation Warp Speed, a FEMA contractor, and other organizations, from who we have received inquiries for our Cryometrix S-90 cryogenic shipping and storage system. These systems can also serve as a cold (e.g. -80C) storage unit once at destination. We do have a large-scale manufacturing capability should these inquires firm up. In terms of the competitive advantages of our products, we believe the Cryometrix liquid nitrogen freezers offer the following principal benefits versus mechanically driven ULT's or the utilization of dry ice. They can: (i) accommodate a wide range of temperature storage conditions (i.e. anywhere from room temperature to as low as -90C); (ii) have a very rapid temperature recovery from door openings, making it safer, for example, in maintaining COVID vaccines at the desired critical temperature; and (iii) the Cryometrix liquid nitrogen system has a very high operational reliability, keeping potential waste of valuable payloads to essentially zero compared to mechanically driven freezers that can be susceptible to failure."
    Bullish
Advertisement
Advertisement